AVTX on XNAS, Health Care, Avalo Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Shares fell 45% in one month, though cash of $462.8M exceeds the $390.3M market value.
BadNet loss of $88.7M over the last 12 months
GoodInstitutional holders rose 16% to 146 in one quarter
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $18.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $121.3M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$18.9M
30 Jun 2026
–
-$36.4M
31 Mar 2026
–
-$19.6M
31 Dec 2025
$59K
-$13.7M
30 Sep 2025
$0
-$30.6M
30 Jun 2025
–
-$20.8M
31 Mar 2025
–
-$13.1M
31 Dec 2024
$192K
-$35.3M
30 Sep 2024
$249K
$23.0M
30 Jun 2024
$0
$98.5M
31 Mar 2024
$0
-$121.3M
31 Dec 2023
$571K
-$8.2M
30 Sep 2023
$236K
-$5.2M
30 Jun 2023
$643K
-$8.2M
31 Mar 2023
$475K
-$10.0M
31 Dec 2022
$896K
-$9.8M
30 Sep 2022
$14.9M
$3.2M
30 Jun 2022
$1.0M
-$13.0M
31 Mar 2022
$1.2M
-$22.1M
31 Dec 2021
$219K
-$19.2M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$88.7M
-$99.9M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-33.6%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$462.8M
$111.6M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$462.8M (net cash)
-$111.6M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$7.55
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.90
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$395K
bought $0, sold $395K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+16%
146 13F filers vs 126
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
71.6M shares held by 13F filers (30 Sep 2026) of 57.8M outstanding (2 Nov 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
15%
8.9M shares sold short (30 Oct 2026) of 57.8M outstanding (2 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
2.1
8.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-26%
12.0M shares sold short in the report before, 8.9M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
37%
37% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 46%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
17
17 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
17×
17 articles in the last 7 days; its usual week has 1.
Price $6.76 on 20 Nov 2026, -62% over 12 months (12-month range $6.63 to $22.87)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $8.3M in the last 12 months (the 12 months before: -$163K).Revenue per quarter. Revenue $59K in the latest quarter, -69% on a year earlier.Capital spending per quarter. Capital spending $0 in the latest quarter.Institutional holders (13F filers). 146 13F filers reported holding it in the latest 13F quarter, +125% on a year earlier.Lobbying spend. Lobbying spend: $0 published in the last 12 months.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $219K, -85% on a year earlier; public on 3 Mar 2022
Quarter ended 31 Mar 2022: $1.2M, +148% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $1.0M, -69% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $14.9M, +1007% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $896K, +309% on a year earlier; public on 30 Mar 2023
Quarter ended 31 Mar 2023: $475K, -60% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $643K, -38% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $236K, -98% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $571K, -36% on a year earlier; public on 30 Mar 2024
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $249K, +5.5% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $192K, -66% on a year earlier; public on 21 Mar 2025
Quarter ended 30 Sep 2025: $0, -100% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $59K, -69% on a year earlier; public on 24 Mar 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $0, -100% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $56K; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $39K; public on 8 Nov 2022
Quarter ended 31 Mar 2023: $158K; public on 5 May 2023
Quarter ended 30 Jun 2023: $0, -100% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $0; public on 30 Mar 2024
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $0; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $0; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $0; public on 21 Mar 2025
Institutional holders (13F filers)
31 Dec 2021 report: 71; public on 14 Feb 2022
31 Mar 2022 report: 68; public on 16 May 2022
30 Jun 2022 report: 53; public on 15 Aug 2022
30 Sep 2022 report: 25; public on 14 Nov 2022
31 Dec 2022 report: 28; public on 14 Feb 2023
31 Mar 2023 report: 32; public on 15 May 2023
30 Jun 2023 report: 25; public on 14 Aug 2023
30 Sep 2023 report: 25; public on 14 Nov 2023
31 Dec 2023 report: 12; public on 14 Feb 2024
31 Mar 2024 report: 18; public on 15 May 2024
30 Jun 2024 report: 20; public on 14 Aug 2024
30 Sep 2024 report: 29; public on 14 Nov 2024
31 Dec 2024 report: 33; public on 14 Feb 2025
31 Mar 2025 report: 34; public on 15 May 2025
30 Jun 2025 report: 35; public on 14 Aug 2025
30 Sep 2025 report: 65; public on 14 Nov 2025
31 Dec 2025 report: 82; public on 17 Feb 2026
31 Mar 2026 report: 95; public on 15 May 2026
30 Jun 2026 report: 126; public on 14 Aug 2026
30 Sep 2026 report: 146; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $30K published
Quarter from 1 Apr 2022: $30K published
Quarter from 1 Jul 2022: $30K published
Quarter from 1 Oct 2022: $30K published
Quarter from 1 Jan 2023: $30K published
Quarter from 1 Apr 2023: $30K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 146 (30 Sep 2026), 4.4× its normal reading; higher than 100% of its own history.
Reported lobbying spend: $30K in Q1 2023, $30K in Q4 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
31 Dec 2023
Ended
Burrell International Group LLCfor Avalo Therapeutics
Burrell International Group LLCfor Avalo Therapeutics
Appropriations and funding for client projects, products, and services; Drug Pricing, Rare Disease Cures, cell and gene therapy.Budget, Health issues, Pharmacy, MED
Two or more unrelated kinds of records unusual within 30 days
18 Nov 2025confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Avalo Therapeutics(AVTX): saw 31 13F filers open a new position in the quarter ended 30 Sep 2025, 2.8× the same quarter last year, while it had 4.1M shares sold short in the 13 Mar 2026 report, 43× the same report last year. Two unrelated kinds of activity within 168 days.
Short interest and volume: Short interest spike, became public on 25 Oct 2025
Institutional holdings: Many funds opening a new position, became public on 14 Nov 2025
Short interest and volume: Short interest spike, became public on 13 Nov 2025
Short interest and volume: Short interest spike, became public on 26 Nov 2025
Short interest and volume: Short interest spike, became public on 10 Dec 2025
Short interest and volume: Short interest spike, became public on 25 Dec 2025
Short interest and volume: Short interest spike, became public on 13 Jan 2026
Short interest and volume: Short interest spike, became public on 28 Jan 2026
Institutional holdings: Many funds opening a new position, became public on 17 Feb 2026
Short interest and volume: Short interest spike, became public on 11 Feb 2026
Short interest and volume: Short interest spike, became public on 26 Feb 2026
Short interest and volume: Short interest spike, became public on 11 Mar 2026
Short interest and volume: Short interest spike, became public on 25 Mar 2026
Short interest and volume: Short interest spike, became public on 11 Apr 2026
The quarter ended 30 Sep 2025 against the 8 quarters before it.
this quarterearliernormal: 6.5See the evidence (14 changes)
Short interest and volume: Short interest spike became public on 25 Oct 2025
Avalo Therapeutics had 1.3M shares sold short in the 15 Oct 2025 report, 26× the same report last year.
This period
1.3M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
66K
Typical spread (median absolute deviation)
27K
How far from its usual level
+24.7
Same report last year
49K
History used
1,506 days
the 15 Oct 2025 report24 earlier reportsnormal: 66K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2025
Avalo Therapeutics saw 31 13F filers open a new position in the quarter ended 30 Sep 2025, 2.8× the same quarter last year.
This period
31 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.2
Same quarter last year
11
History used
1,461 days
the quarter ended 30 Sep 20258 earlier quartersnormal: 6.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 13 Nov 2025
Avalo Therapeutics had 1.3M shares sold short in the 31 Oct 2025 report, 134× the same report last year.
This period
1.3M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
80K
Typical spread (median absolute deviation)
36K
How far from its usual level
+23.6
Same report last year
10K
History used
1,522 days
the 31 Oct 2025 report24 earlier reportsnormal: 80K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Nov 2025
Avalo Therapeutics had 1.8M shares sold short in the 14 Nov 2025 report, 188× the same report last year.
This period
1.8M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
85K
Typical spread (median absolute deviation)
39K
How far from its usual level
+30.4
Same report last year
9,775
History used
1,536 days
the 14 Nov 2025 report24 earlier reportsnormal: 85K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Dec 2025
Avalo Therapeutics had 1.8M shares sold short in the 28 Nov 2025 report, 354× the same report last year.
This period
1.8M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
88K
Typical spread (median absolute deviation)
42K
How far from its usual level
+28.2
Same report last year
5,218
History used
1,550 days
the 28 Nov 2025 report24 earlier reportsnormal: 88K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Dec 2025
Avalo Therapeutics had 1.9M shares sold short in the 15 Dec 2025 report, 81× the same report last year.
This period
1.9M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
90K
Typical spread (median absolute deviation)
44K
How far from its usual level
+27.0
Same report last year
23K
History used
1,567 days
the 15 Dec 2025 report24 earlier reportsnormal: 90K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Jan 2026
Avalo Therapeutics had 2.6M shares sold short in the 31 Dec 2025 report, 128× the same report last year.
This period
2.6M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
93K
Typical spread (median absolute deviation)
47K
How far from its usual level
+35.4
Same report last year
20K
History used
1,583 days
the 31 Dec 2025 report24 earlier reportsnormal: 93K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Jan 2026
Avalo Therapeutics had 3.0M shares sold short in the 15 Jan 2026 report, 53× the same report last year.
This period
3.0M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
98K
Typical spread (median absolute deviation)
52K
How far from its usual level
+37.3
Same report last year
56K
History used
1,598 days
the 15 Jan 2026 report24 earlier reportsnormal: 98K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 17 Feb 2026
Avalo Therapeutics saw 30 13F filers open a new position in the quarter ended 31 Dec 2025, 4.3× the same quarter last year.
This period
30 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
2
How far from its usual level
+7.8
Same quarter last year
7
History used
1,553 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 6.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Feb 2026
Avalo Therapeutics had 3.2M shares sold short in the 30 Jan 2026 report, 74× the same report last year.
This period
3.2M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
108K
Typical spread (median absolute deviation)
62K
How far from its usual level
+33.5
Same report last year
43K
History used
1,613 days
the 30 Jan 2026 report24 earlier reportsnormal: 108K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
Avalo Therapeutics had 3.6M shares sold short in the 13 Feb 2026 report, 47× the same report last year.
This period
3.6M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
117K
Typical spread (median absolute deviation)
71K
How far from its usual level
+33.0
Same report last year
76K
History used
1,627 days
the 13 Feb 2026 report24 earlier reportsnormal: 117K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Mar 2026
Avalo Therapeutics had 3.7M shares sold short in the 27 Feb 2026 report, 41× the same report last year.
This period
3.7M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
141K
Typical spread (median absolute deviation)
95K
How far from its usual level
+25.1
Same report last year
91K
History used
1,641 days
the 27 Feb 2026 report24 earlier reportsnormal: 141K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Mar 2026
Avalo Therapeutics had 4.1M shares sold short in the 13 Mar 2026 report, 43× the same report last year.
This period
4.1M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
183K
Typical spread (median absolute deviation)
140K
How far from its usual level
+18.8
Same report last year
96K
History used
1,655 days
the 13 Mar 2026 report24 earlier reportsnormal: 183K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Apr 2026
Avalo Therapeutics had 5.5M shares sold short in the 31 Mar 2026 report, 48× the same report last year.
This period
5.5M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
723K
Typical spread (median absolute deviation)
671K
How far from its usual level
+4.8
Same report last year
116K
History used
1,673 days
the 31 Mar 2026 report24 earlier reportsnormal: 723K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
saw 30 13F filers open a new position in the quarter ended 31 Mar 2026, 6.0× the same quarter last year.
Same quarter last year: 5; its normal quarter is 7.5.
See the evidence
This period
30 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
7.5
Typical spread (median absolute deviation)
3
How far from its usual level
+5.1
Same quarter last year
5
History used
1,643 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 7.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 5.5M shares sold short in the 31 Mar 2026 report, 48× the same report last year.
Same report last year: 116K; its normal report is 723K.
See the evidence
This period
5.5M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
723K
Typical spread (median absolute deviation)
671K
How far from its usual level
+4.8
Same report last year
116K
History used
1,673 days
the 31 Mar 2026 report24 earlier reportsnormal: 723K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.1M shares sold short in the 13 Mar 2026 report, 43× the same report last year.
Same report last year: 96K; its normal report is 183K.
See the evidence
This period
4.1M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
183K
Typical spread (median absolute deviation)
140K
How far from its usual level
+18.8
Same report last year
96K
History used
1,655 days
the 13 Mar 2026 report24 earlier reportsnormal: 183K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.7M shares sold short in the 27 Feb 2026 report, 41× the same report last year.
Same report last year: 91K; its normal report is 141K.
See the evidence
This period
3.7M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
141K
Typical spread (median absolute deviation)
95K
How far from its usual level
+25.1
Same report last year
91K
History used
1,641 days
the 27 Feb 2026 report24 earlier reportsnormal: 141K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.6M shares sold short in the 13 Feb 2026 report, 47× the same report last year.
Same report last year: 76K; its normal report is 117K.
See the evidence
This period
3.6M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
117K
Typical spread (median absolute deviation)
71K
How far from its usual level
+33.0
Same report last year
76K
History used
1,627 days
the 13 Feb 2026 report24 earlier reportsnormal: 117K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 30 13F filers open a new position in the quarter ended 31 Dec 2025, 4.3× the same quarter last year.
Same quarter last year: 7; its normal quarter is 6.5.
See the evidence
This period
30 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
2
How far from its usual level
+7.8
Same quarter last year
7
History used
1,553 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 6.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 3.2M shares sold short in the 30 Jan 2026 report, 74× the same report last year.
Same report last year: 43K; its normal report is 108K.
See the evidence
This period
3.2M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
108K
Typical spread (median absolute deviation)
62K
How far from its usual level
+33.5
Same report last year
43K
History used
1,613 days
the 30 Jan 2026 report24 earlier reportsnormal: 108K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.0M shares sold short in the 15 Jan 2026 report, 53× the same report last year.
Same report last year: 56K; its normal report is 98K.
See the evidence
This period
3.0M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
98K
Typical spread (median absolute deviation)
52K
How far from its usual level
+37.3
Same report last year
56K
History used
1,598 days
the 15 Jan 2026 report24 earlier reportsnormal: 98K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.6M shares sold short in the 31 Dec 2025 report, 128× the same report last year.
Same report last year: 20K; its normal report is 93K.
See the evidence
This period
2.6M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
93K
Typical spread (median absolute deviation)
47K
How far from its usual level
+35.4
Same report last year
20K
History used
1,583 days
the 31 Dec 2025 report24 earlier reportsnormal: 93K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.9M shares sold short in the 15 Dec 2025 report, 81× the same report last year.
Same report last year: 23K; its normal report is 90K.
See the evidence
This period
1.9M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
90K
Typical spread (median absolute deviation)
44K
How far from its usual level
+27.0
Same report last year
23K
History used
1,567 days
the 15 Dec 2025 report24 earlier reportsnormal: 90K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.8M shares sold short in the 28 Nov 2025 report, 354× the same report last year.
Same report last year: 5,218; its normal report is 88K.
See the evidence
This period
1.8M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
88K
Typical spread (median absolute deviation)
42K
How far from its usual level
+28.2
Same report last year
5,218
History used
1,550 days
the 28 Nov 2025 report24 earlier reportsnormal: 88K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.8M shares sold short in the 14 Nov 2025 report, 188× the same report last year.
Same report last year: 9,775; its normal report is 85K.
See the evidence
This period
1.8M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
85K
Typical spread (median absolute deviation)
39K
How far from its usual level
+30.4
Same report last year
9,775
History used
1,536 days
the 14 Nov 2025 report24 earlier reportsnormal: 85K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 31 13F filers open a new position in the quarter ended 30 Sep 2025, 2.8× the same quarter last year, while it had 4.1M shares sold short in the 13 Mar 2026 report, 43× the same report last year. Two unrelated kinds of activity within 168 days.
See the evidence (14 changes)
Short interest and volume: Short interest spike became public on 25 Oct 2025
Avalo Therapeutics had 1.3M shares sold short in the 15 Oct 2025 report, 26× the same report last year.
This period
1.3M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
66K
Typical spread (median absolute deviation)
27K
How far from its usual level
+24.7
Same report last year
49K
History used
1,506 days
the 15 Oct 2025 report24 earlier reportsnormal: 66K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2025
Avalo Therapeutics saw 31 13F filers open a new position in the quarter ended 30 Sep 2025, 2.8× the same quarter last year.
This period
31 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.2
Same quarter last year
11
History used
1,461 days
the quarter ended 30 Sep 20258 earlier quartersnormal: 6.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 13 Nov 2025
Avalo Therapeutics had 1.3M shares sold short in the 31 Oct 2025 report, 134× the same report last year.
This period
1.3M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
80K
Typical spread (median absolute deviation)
36K
How far from its usual level
+23.6
Same report last year
10K
History used
1,522 days
the 31 Oct 2025 report24 earlier reportsnormal: 80K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Nov 2025
Avalo Therapeutics had 1.8M shares sold short in the 14 Nov 2025 report, 188× the same report last year.
This period
1.8M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
85K
Typical spread (median absolute deviation)
39K
How far from its usual level
+30.4
Same report last year
9,775
History used
1,536 days
the 14 Nov 2025 report24 earlier reportsnormal: 85K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Dec 2025
Avalo Therapeutics had 1.8M shares sold short in the 28 Nov 2025 report, 354× the same report last year.
This period
1.8M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
88K
Typical spread (median absolute deviation)
42K
How far from its usual level
+28.2
Same report last year
5,218
History used
1,550 days
the 28 Nov 2025 report24 earlier reportsnormal: 88K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Dec 2025
Avalo Therapeutics had 1.9M shares sold short in the 15 Dec 2025 report, 81× the same report last year.
This period
1.9M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
90K
Typical spread (median absolute deviation)
44K
How far from its usual level
+27.0
Same report last year
23K
History used
1,567 days
the 15 Dec 2025 report24 earlier reportsnormal: 90K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Jan 2026
Avalo Therapeutics had 2.6M shares sold short in the 31 Dec 2025 report, 128× the same report last year.
This period
2.6M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
93K
Typical spread (median absolute deviation)
47K
How far from its usual level
+35.4
Same report last year
20K
History used
1,583 days
the 31 Dec 2025 report24 earlier reportsnormal: 93K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Jan 2026
Avalo Therapeutics had 3.0M shares sold short in the 15 Jan 2026 report, 53× the same report last year.
This period
3.0M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
98K
Typical spread (median absolute deviation)
52K
How far from its usual level
+37.3
Same report last year
56K
History used
1,598 days
the 15 Jan 2026 report24 earlier reportsnormal: 98K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 17 Feb 2026
Avalo Therapeutics saw 30 13F filers open a new position in the quarter ended 31 Dec 2025, 4.3× the same quarter last year.
This period
30 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
2
How far from its usual level
+7.8
Same quarter last year
7
History used
1,553 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 6.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Feb 2026
Avalo Therapeutics had 3.2M shares sold short in the 30 Jan 2026 report, 74× the same report last year.
This period
3.2M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
108K
Typical spread (median absolute deviation)
62K
How far from its usual level
+33.5
Same report last year
43K
History used
1,613 days
the 30 Jan 2026 report24 earlier reportsnormal: 108K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
Avalo Therapeutics had 3.6M shares sold short in the 13 Feb 2026 report, 47× the same report last year.
This period
3.6M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
117K
Typical spread (median absolute deviation)
71K
How far from its usual level
+33.0
Same report last year
76K
History used
1,627 days
the 13 Feb 2026 report24 earlier reportsnormal: 117K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Mar 2026
Avalo Therapeutics had 3.7M shares sold short in the 27 Feb 2026 report, 41× the same report last year.
This period
3.7M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
141K
Typical spread (median absolute deviation)
95K
How far from its usual level
+25.1
Same report last year
91K
History used
1,641 days
the 27 Feb 2026 report24 earlier reportsnormal: 141K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Mar 2026
Avalo Therapeutics had 4.1M shares sold short in the 13 Mar 2026 report, 43× the same report last year.
This period
4.1M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
183K
Typical spread (median absolute deviation)
140K
How far from its usual level
+18.8
Same report last year
96K
History used
1,655 days
the 13 Mar 2026 report24 earlier reportsnormal: 183K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Apr 2026
Avalo Therapeutics had 5.5M shares sold short in the 31 Mar 2026 report, 48× the same report last year.
This period
5.5M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
723K
Typical spread (median absolute deviation)
671K
How far from its usual level
+4.8
Same report last year
116K
History used
1,673 days
the 31 Mar 2026 report24 earlier reportsnormal: 723K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Nov 2025Institutional holdings change
saw 31 13F filers open a new position in the quarter ended 30 Sep 2025, 2.8× the same quarter last year.
Same quarter last year: 11; its normal quarter is 6.5.
See the evidence
This period
31 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.2
Same quarter last year
11
History used
1,461 days
the quarter ended 30 Sep 20258 earlier quartersnormal: 6.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 1.3M shares sold short in the 31 Oct 2025 report, 134× the same report last year.
Same report last year: 10K; its normal report is 80K.
See the evidence
This period
1.3M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
80K
Typical spread (median absolute deviation)
36K
How far from its usual level
+23.6
Same report last year
10K
History used
1,522 days
the 31 Oct 2025 report24 earlier reportsnormal: 80K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 15 Oct 2025 report, 26× the same report last year.
Same report last year: 49K; its normal report is 66K.
See the evidence
This period
1.3M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
66K
Typical spread (median absolute deviation)
27K
How far from its usual level
+24.7
Same report last year
49K
History used
1,506 days
the 15 Oct 2025 report24 earlier reportsnormal: 66K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 30 Sep 2025 report, 23× the same report last year.
Same report last year: 54K; its normal report is 56K.
See the evidence
This period
1.2M (the 30 Sep 2025 report)
Normal report (median of 24 earlier)
56K
Typical spread (median absolute deviation)
34K
How far from its usual level
+23.7
Same report last year
54K
History used
1,491 days
the 30 Sep 2025 report24 earlier reportsnormal: 56K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 168 entries; narrow the window or the kind of data to see older ones.
Not listed: 236 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001534120
Ticker
AVTX
Domain
avalotx.com
Hq location
PA|WAYNE|19087 (1 unverified)
Lobbying client
avalo therapeutics
Name
Avalo Therapeutics, Inc., Cerecor Inc.
Uei
J7WVEQTH1ML6
Federal lobbying disclosures (LDA)2 records, 33 data points26 Mar 2021 to 31 Dec 2023
SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)281 records12 Jan 2016 to 5 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)735 data points31 Dec 2012 to 2 Nov 2026
SEC Form 4 insider transactions146 records, 476 data points9 May 2017 to 18 Sep 2026
FINRA short interest (twice monthly)372 data points31 Aug 2021 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2632 data points26 Aug 2021 to 20 Nov 2026
USASpending.gov federal awards2 records, 21 data points8 Aug 2011 to 1 Oct 2021